LIXTE Biotechnology Holdings Inc. presented preliminary results from a clinical trial evaluating its proprietary compound LB-100 in combination with dostarlimab at the 2026 Society of Gynecologic Oncology conference in San Juan, Puerto Rico. Interim data from 20 evaluable patients demonstrated a 40% disease control rate and encouraging survival trends with an acceptable safety profile, supporting continued enrollment of an expanded cohort.
The company is investigating the combination's potential to enhance immunotherapy response in ovarian clear cell carcinoma, a particularly challenging form of cancer. These results are significant because they represent progress in a field where treatment options remain limited for many patients with advanced ovarian cancers. The disease control rate observed in this interim analysis suggests the combination therapy may help stabilize cancer progression in a substantial portion of patients.
LB-100 is LIXTE's lead compound and first-in-class clinical PP2A inhibitor that has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. The compound is part of a pioneering effort in an entirely new field of cancer biology called activation lethality that is advancing a new treatment paradigm.
This development matters because ovarian clear cell carcinoma represents a subtype that has historically shown limited response to conventional therapies. The interim results suggest that combining LB-100 with immunotherapy agents like dostarlimab may overcome some resistance mechanisms, potentially offering new hope for patients with this specific cancer type. The acceptable safety profile reported is particularly important as it indicates the combination may be manageable for patients already dealing with the challenges of cancer treatment.
LIXTE's novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma. Additional information about the company's research can be found at https://www.lixte.com. Through its wholly owned subsidiary, Liora Technologies Europe Ltd., the company is also developing electronically controlled proton therapy systems, with more information available at https://www.lioratechnologies.com.
The implications of these interim results extend beyond the specific patient population in the trial. If confirmed in larger studies, this approach could validate the activation lethality paradigm and potentially be applied to other cancer types where immunotherapy resistance remains a significant challenge. The continued enrollment of an expanded cohort will provide more robust data on efficacy and safety, potentially moving this combination closer to regulatory review and eventual patient access.
